Milrinone Versus Dobutamine in Critically Ill Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.
Also called NCT03207165
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 192 participants
- Registry
-
NCT03207165
-
- Other papers using this trial's data
- Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial
- Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock
- Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial
- Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03207165. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-30 (actual); primary completion 2020-06-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Milrinone Versus Dobutamine in Critically Ill Patients
- Condition
- Low Cardiac Output Syndrome
- Condition
- Cardiogenic Shock
- Condition
- Acute Coronary Syndrome
- Condition
- Pulmonary Edema
- Intervention (Drug)
- Milrinone
- Intervention (Drug)
- Dobutamine
- Lead sponsor
- Ottawa Heart Institute Research Corporation
Record details
- Record id
cardio:ct-nct03207165- Content hash
39cfb2890144146f40be72c6776801befc5ac2caa80cc478290d93a950ef5fd3